SCHEMBL3757246

SCHEMBL3757246

CCOc1nc(N)nc2ncc(-c3ccccc3NS(=O)(=O)c3ccc(C)cc3)nc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 9/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPT P10636 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
USP2 O75604 1/20 0.47
POLB P06746 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
NOD2 Q9HC29 1/20 0.47
CA12 O43570 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
MCOLN3 Q8TDD5 1/20 0.44
PIK3CA P42336 2/20 0.42
MTOR P42345 2/20 0.42
KMT2A Q03164 4/20 0.41
TDP1 Q9NUW8 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
HTT P42858 2/20 0.41
SLC40A1 Q9NP59 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3765507 0.88 ALOX5AP (0.44) PIK3CAHTTHSD17B10
SCHEMBL3770164 0.83 MAPT (0.54) LMNAALDH1A1MAPTKMT2AMEN1
SCHEMBL3763792 0.79 NOS1 (0.39) MAPTPOLBKMT2AMEN1SMN1; SMN2
SCHEMBL3760760 0.78 ALOX5AP (0.42) CA12CA2CA9CDK2
SCHEMBL3765094 0.78 NOS1 (0.56) LMNAALDH1A1MAPTL3MBTL1USP2
SCHEMBL3769692 0.78 NOS1 (0.44) ALDH1A1CDK2NPC1
SCHEMBL3762339 0.75 NOS1 (0.44) ALDH1A1KDM4E
SCHEMBL3755577 0.75 NOS1 (0.61) PIK3CA
SCHEMBL3760449 0.74 NOS1 (0.44) LMNAALDH1A1MAPTPOLBCYP2C9
SCHEMBL3766603 0.74 PTPN1 (0.47) LMNAALDH1A1MAPTL3MBTL1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190152974-A1 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS GILEAD SCIENCES, INC. 2019-05-23 US claimed
US-20100305117-A1 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-12-02 US claimed
WO-2008009079-A2 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-20190152974-A1 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS GILEAD SCIENCES, INC. 2019-05-23 US disclosed
US-10144736-B2 Substituted pteridines useful for the treatment and prevention of viral infections GILEAD SCIENCES, INC. (US) 2018-12-04 US disclosed
US-20100305117-A1 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-12-02 US disclosed
WO-2008009079-A2 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190152974-A1 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS HCCS, DPYD, HAVCR2 LMNA 2340/4885ALDH1A1 1548/4885MAPT 4683/4885
US-10144736-B2 Substituted pteridines useful for the treatment and prevention of viral infections HCCS, DPYD, HAVCR2 LMNA 2340/4885ALDH1A1 1548/4885MAPT 4683/4885
US-20100305117-A1 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS HCCS, DPYD, HAVCR2 LMNA 2340/4885ALDH1A1 1548/4885MAPT 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.